{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": [
        "Hemoglobin level < 8 g/dL (5.0 mmol/L)",
        "Platelet count < 75x10\u2079/L",
        "Creatinine clearance < 30 ml/min (Cockcroft-Gault)",
        "ALT level \u22653 times the upper limit of normal (ULN)",
        "Bilirubin level \u22652 times the ULN",
        "Hepatic disease associated with coagulopathy and clinically relevant bleeding risk"
    ]
}